The EBV titer in the plasma of circulating blood confirmed the presence of significant EBV lytic activation in advanced NPC samples (Fig 6E), The positive areas of CD1a and CD163 and the number of blood vessels in each sample were quantified by Image J (Fig 6F). This evidence concerns the gene CD163 and nasopharyngeal carcinoma.